You are here » Home » Companies » Company Overview » ACE Laboratories Ltd

ACE Laboratories Ltd.

BSE: 526077 Sector: Health care
NSE: ACELAB ISIN Code: N.A.
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty

ACE Laboratories Ltd. (ACELAB) - Director Report

Company director report

ACE LABORATORIES LIMITED. DIRECTOR'S REPORT To the Members of ACE LABORATORIES LIMITED Your Directors have pleasure in presenting the 13th Annual Report of ACE LABORATORIES LlMlTED together with the audited statement of accounts for the year ended 30th June, 1998. YEAR IN RETROSPECT :- The Indian Economy has been witnessing continuous slowdown for the past few years due to political changes and economic uncertainties. In tune with the overall industrial backdrop, there has been a decline in the growth of pharmaceutical Industry too. However, despite this downward trend, Ace Lab has been able to maintain an encouraging growth of around 30% in terms of turnover and 32% in terms of profitability as compared to 16% overall growth of Indian Pharma Industry. The turnover registered a growth of 29.60% at Rs. 13326.44 lacs and Net Profit stood at Rs. 1174.84 lacs thereby maintaining a rise of 32.45% over the previous year. The net profit margin has also improved due to economy of production. On the marketing front, dedicated efforts being made toward exploring new avenues for exports. In the domestic market, aggressive efforts are being made to increase the market share by introducing new products. Brand building exercise are being strongly followed. Efforts are also on to acquire existing established brands. The marketing team has been strengthened by reorganising the entire marketing setup and induction of experienced sales personnel. The injectable section at Alwar also started production during the year. The Alwar formulation plant has been suitably modified keeping in view the WHO and ISO guidelines. DIVIDEND :- The Directors recommended payment of Dividend on equity shares at the rate of 18% (previous year 18% on the Paid Up Equity Shares of the Company. The Dividend, as recommended, if approved by the members will be paid to those shareholders whose name appears on the Register of Members on the record date to be fixed for this purpose. It is noteworthy that the company is maintaining dividend payment for the last 7 years despite the heavy utilisation of its internal accruals in funding the new projects. The Dividend on Preference Shares shall be paid in terms of the issue at the rate of 13%,15% and 16% (prorata where ever applicable). EXPORTS :- On the export front, our efforts are aimed at internationalisation of our base by strategic alliances and establishing subsidiaries, joint ventures, marketing offices and affiliates in target markets. During the year under review, the export turnover reached at 21% of total sale by achieving export of Rs 2803.01 lacs as compared to Rs. 1353.50 lacs in the previous year. This immense leap has been made possible due to company's strategic expansion in various parts of the world. It has entered into marketing tie up in East Africa. An agreement has been entered into for marketing in whole of Southern Africa. Apart from these markets, Company has also made a dent in the markets of various West African Countries. The marketing office set up in Uzbekistan will cater to the Central Asia Region & some CIS Countries. RESEARCH & DEVELOPMENT :- To meet the challenges of post GATT era, major emphasis is being made in the R&D arena. The R&D is aimed at development of new product and process and new technologies for import substitution apart from maintaining high quality standard, advanced pharmakokinetics and accelerated stability studies of existing and new products. Your Company has also made major advancement in commercialisation of new formulations which will be launched in domestic market after successful clinical tests. The new R & D centre alongwith a well equipped Pilot Plant is under commissioning at Alwar This facility would provide major thrust in areas of Developments and standardization of process for Bulk Drugs and intermediates, custom synthesis and cost improvement programme for existing range of products. NEW PROJECT :- Your Company has acquired the technology for manufacture of Liposomal Amphotericin-B, from National Research and Development Corporation (A Govt. enterprise). This is a wonder drug used as most potent systemic antifungal drug for almost four decades. The manufacturing facility has been set up at Alwar. Ace Laboratories would be third Company in the world and first in Asia to manufacture Liposomal Amphotericin-B. BULK DRUG AND INTERMEDIATE PROJECT :- Our recently implemented Bulk Drug Project at Alwar is equipped with the facilities for manufacture of various Bulk Drugs belonging to therapeutic categories of Antibiotics, Antibacterial and Antimalarials. Some modification work has been carried out in the intermediate project to ensure better quality and yields. The Intermediate project has been delayed and the cost of the project has increased by approx. 10% mainly due to cost and time escalatinn. PROSPECTS FOR THE CURRENT YEAR :- With the Bulk Drug Project including Amphotericin-B and the intermediate project has been implemented, the Directors are hopeful of maintaining higher performance in terms of turnover and profitability in the current year too. DIRECTORS :- Sh. Chiman Lal Agarwal has resigned from the Directorship and also from the post of Executive Director of the Company w.e.f. 25/04/ 98. The Board wishes to place on record his services to the Company during his tenure. Sh. K D Jaitly and Sh. Umesh Bal Sharma retires by rotation and being eligible offers themselves for reappointment. The members are requested to consider their re-appointment as Director of the Company under Section 255 of the Companies Act, 1956. During the year M/s SICOM Limited Mumbai, has appointed Mr V. M. Paradkar as its Nominee Director The Board of Directors welcomes Mr Paradkar as a Member of the Board. AUDITORS :- M/s Gyan Chandra & Co, Chartered Accountants the statutory auditors of the company retires at the conclusion of the Annual General Meeting and being eligible, offered themselves for re-appointment. Intimation under section 2241B] has been received from them to the effect that their re-appointment if approved, will be within the prescribed limit. The Reports of the auditors are self-explanatory and suitably explained in Notes to the Accountants. FIXED DEPOSITS :- The amount of Fixed Deposit from the public & others outstanding as on 30th June 1998 stood at Rs.384.47 lacs. As on 30.6.98 there is no overdue deposit. The amount of deposit for which Payment Instruments already been issued but unclaimed as on 30.6.98 stood at Rs.12.10 Lacs. EMPLOYEES :- Statutory information regarding remunerations paid in excess of limit prescribed under Companies Act, 1956 are given in Annexure II. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO :- The information relating to conservation of energy, technology, absorption and foreign exchange earning and outgo are given separately in annexure 1, which forms part of this report. INDUSTRIAL RELATION :- The relations between labour and management continue to be most cordial during the year under review. ACKNOWLEDGEMENT :- Your directors wish to thank the Government, financial institutions and banks for their regular assistance and guidance. The directors also wish to place on record their appreciation of the dedicated services rendered by the staff and workers with loyalty and sense of belonging as a family member The Board also acknowledge the cooperation extended by the stockist, agents, suppliers and distributors. For and on behalf of the Board DATED : 28th JULY, 1998. AJIT CHAND SRIMAL PLACE : New Delhi Chairman & Managing Director ANNEXURE I TO DIRECTOR'S REPORT Information as per Section 217[1][e] of The Companies Act, 1956 read with the rules framed thereunder. A. CONSERVATION OF ENERGY a] Energy conservation measure undertaken: Energy conservation measures considered as major area of emphasis for the company The company has modified the plant parameters suitably as per the advice of the collaborators, technology transferor and company's expertise to increase efficiency in operation at its new plants at Alwar. b] Additional investments and proposals, if any. Nil B. RESEARCH & DEVELOPMENT The objective of Company's Research & Development ( R&D) efforts have been explained in the Director's Report. The Company has three Research Unit situated at Delhi formulation unit, Alwar formulation Unit and Alwar Intermediate Unit. The R & D unit at Alwar intermediate project is an integral part of the Intermediate and Bulk Drug project and would be utilised to develop the process of manufacturing for new molecules. This R & D Unit is under implementation with total cost of Rs. 420 lacs. The total expenditure incurred on Research & Development are as follows:- 1997-98 1996-97 a) On capital Account :- 22.11 * 62.09 b) On Revenue Account :- 19.56 17.76 Total c) Total R&D expenditure as 41.67 79.85 percentage of turnover :- 0.31 0.61 [*Amount incurred on Capital work in progress not included] C. TECHNOLOGY ABSORPTION, ADAPTATION & INNOVATION :- The manufacturing process for formulations are based on indigenous technology and the company is working out towards development of new formulations besides its continuous efforts for development of its existing technologies and products. Technology for manufacture of EMME & TEOF is being obtained from China for which company's scientists have been trained by the collaborator Company has also purchased technology from Korea for manufacture of Cephelosporin and the absorption of this technology is going on as per schedule. During the year under review. Your Company has acquired the technology for manufacture of Liposomal Amphotericin-B, from National Research and Development Corporation. D. FOREIGN EXCHANGE EARNINGS AND OUTGO :- The foreign exchange outgo during the year stand at Rs.554.16 lacs [previous year 566.72 lacs) on account of Raw materials and Rs. 157.49 lacs [previous year 87.92 lacs] on other accounts. The foreign exchange earning are from export business which stand at Rs.2707.44 lacs.[ previous year 1230.85 lacs) The imported raw materials constitute 5.48% of total consumption [previous year 6.53%). Detail of earning and outgo are given in Notes to the Account. at point No 5 [H) to [K] For and on behalf of the Board DATED : 28th JULY, 1998. (AJIT CHAND SRIMAL) PLACE : New Delhi Chairman & Managing Director

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard